For roughly a third of the world's 50 million epilepsy patients, drugs stop working. The next option used to be removing brain tissue. A Chinese implant is now trying a quieter fix: listen to the brain, and interrupt the storm the moment it forms.
The implant that waits
The device is called NEO-ONE ANS, made by Neuracle (博睿康), a Shanghai-based brain–computer interface (脑机接口) company. It is a responsive neurostimulation system: a coin-sized unit buried under the skull, with electrodes that sit on the brain's protective membrane and record electrical activity around the clock. When its decoder spots the signature of an oncoming seizure, it fires a small stimulating pulse to disrupt it — then goes quiet again.
That "close the loop" design is the whole point. Older open-loop stimulators fire on a fixed schedule whether or not a seizure is coming. A closed-loop system only acts on evidence, which in theory means less unnecessary current in the brain and tighter control. The electrodes target deep temporal structures such as the hippocampus, the usual origin of focal seizures that cannot be safely resected.
From a Tsinghua idea to the clinic
The underlying NEO platform traces to 2013, when a Tsinghua University team led by Hong Bo proposed a semi-invasive approach — placing electrodes just outside the brain's dura mater, balancing signal quality against surgical risk, and powering the device wirelessly so no battery sits inside the body. The first human implant happened on 24 October 2023 at Xuanwu Hospital (宣武医院) in Beijing, described as China's first minimally invasive implantable BCI procedure.
For epilepsy, the ANS product entered China's special review pathway for innovative medical devices at the National Medical Products Administration in March 2025 and moved into a confirmatory multi-center clinical stage. By early 2026 Neuracle reported 36 implants completed — 4 in a feasibility phase and 32 in the confirmatory trial — with primary endpoints collected by November 2025.
What the early data actually shows
Hard numbers are still thin, which is normal this early. A peer-reviewed study in the Chinese Journal of Neurosurgery (2024), led at the Second Affiliated Hospital of Zhejiang University, followed six drug-resistant epilepsy patients given a domestic closed-loop responsive neurostimulation system. Seizure frequency fell about 39% at ten months and 44% at thirteen months after activation, with no surgery- or device-related adverse events reported.
Those are small, early figures. Broader claims that closed-loop neuromodulation can cut seizure frequency by 40–80% come from international literature and vendor framing, not from a large Chinese trial yet. The honest read: the direction is encouraging, the evidence base is still being built.
Why a hospital in Beijing matters
Xuanwu Hospital's neurosurgery group, led by professor Zhao Guoguang (赵国光), runs the multi-center ANS trial for epilepsy and began recruiting patients under an ethics approval granted in 2023. The target is patients whose seizures are focal but who cannot or will not undergo resection surgery — exactly the group with few good options.
The same NEO platform already scored a bigger regulatory win elsewhere: its spinal-cord-injury product, NEO-ONE SCI, received China's Class III medical-device registration on 13 March 2026 — described as the world's first approved implantable brain–computer interface device, aimed at helping tetraplegic patients regain hand function.
What readers can do now
- If you follow medtech, track NMPA innovative-device entries (March 2025 for ANS) as the real regulatory milestone, not press releases.
- If you or a family member has drug-resistant epilepsy, ask a comprehensive epilepsy center about responsive neurostimulation trials; this is still investigational in China for epilepsy.
- If you report on BCI, separate the spinal-cord product (approved) from the epilepsy product (in trial) — they are on the same platform but at different stages.
Honest limitations
Device identity and mechanism (NEO-ONE ANS, Neuracle/博睿康, coin-sized epidural closed-loop responsive neurostimulation, wireless-powered, ages 6+) come from Neuracle IPO filings reported by 新浪财经 and 东方财富, and from the Shanghai Pudong government site. Regulatory milestones (first NEO implant 24 Oct 2023 at Xuanwu Hospital; NEO-ONE SCI Class III registration 13 Mar 2026, described as world's first approved implantable BCI device; ANS entering NMPA innovative-device special review Mar 2025; 36 implants with primary endpoint Nov 2025) are from Neuracle filings, 澎湃新闻 and Pudong government. Xuanwu Hospital's ANS epilepsy trial and Zhao Guoguang as lead are from the hospital's own recruitment notice (ethics no. 临械审[2023]029号-002). The 39%/44% seizure reduction is from a peer-reviewed Chinese Journal of Neurosurgery paper (2024, Zhejiang Univ 2nd Hospital, n=6, National Key R&D 科技创新2030 project). The 40–80% range is international/vendor literature, not a verified Chinese trial result. Global epilepsy prevalence (~50M, ~30% drug-resistant) is standard epidemiological framing. This article contains no RMB amounts, so no currency conversion applies. Not medical advice.